Trial Profile
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary) ; Fenofibrate; Ursodeoxycholic acid
- Indications Primary biliary cirrhosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TARGET-PBC
- 12 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2026.
- 12 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2026.
- 19 Sep 2019 Status changed from recruiting to active, no longer recruiting.